Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
15.39
-0.19 (-1.22%)
At close: Jul 17, 2026, 4:00 PM EDT
15.40
+0.01 (0.06%)
After-hours: Jul 17, 2026, 6:55 PM EDT
Personalis Revenue
Personalis had revenue of $15.47M in the quarter ending March 31, 2026, a decrease of -24.91%. This brings the company's revenue in the last twelve months to $64.52M, down -24.71% year-over-year. In the year 2025, Personalis had annual revenue of $69.65M, down -17.69%.
Revenue (ttm)
$64.52M
Revenue Growth
-24.71%
P/S Ratio
24.98
Revenue / Employee
$248,135
Employees
260
Market Cap
1.61B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69.65M | -14.97M | -17.69% |
| Dec 31, 2024 | 84.61M | 11.13M | 15.15% |
| Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
| Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
| Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
| Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
| Dec 31, 2019 | 65.21M | 27.43M | 72.62% |
| Dec 31, 2018 | 37.77M | 28.38M | 302.15% |
| Dec 31, 2017 | 9.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.14B |
| Myriad Genetics | 829.00M |
| NeoGenomics | 745.97M |
| OPKO Health | 581.12M |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Castle Biosciences | 339.92M |
PSNL News
- 23 hours ago - Personalis price target raised to $17 from $12 at Needham - TheFly
- 1 day ago - Personalis attracting takeover interest, Street Insider says - TheFly
- 1 day ago - Personalis moves off low after blog claims company exploring possible sale - TheFly
- 2 days ago - Personalis price target raised to $18 from $10 at TD Cowen - TheFly
- 4 days ago - Personalis’ NeXT Personal test granted UKCA marking - TheFly
- 4 days ago - Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain - Business Wire
- 8 days ago - Personalis price target raised to $13 from $9 at Morgan Stanley - TheFly
- 5 weeks ago - Personalis’ specimen collection kits obtain European Union CE-IVD mark - TheFly